(E27038) Stock Price

UMN Pharma is a biopharmaceutical company with a mission to rapidly develop innovative biopharmaceuticals in therapeutic areas where adequate treatment options do not exist. The company operates two business segments: "Next-Generation Biopharmaceutical In-House Development" and "Biopharmaceutical Contract Manufacturing." Its operations are centered on the development of human infectious disease prevention vaccines.

The company's primary revenue sources are upfront payments from licensing agreements when it out-licenses self-developed vaccines to pharmaceutical companies, development milestone fees, and running royalties following product launch. Additionally, the company generates revenue from contract manufacturing of biopharmaceuticals utilizing its Yokohama Research Institute, Akita Research Institute, and Akita Manufacturing Facility. It provides high-value-added services focused on CMC development and manufacturing feasibility studies in the early to mid-stage development phases.

The company's development pipeline includes multiple human infectious disease prevention vaccines targeting norovirus, rotavirus, and influenza virus. All of these are in the basic research stage and are being developed based on the company's proprietary next-generation logical vaccine concept. In October 2017, the company entered into a capital and business alliance with Shionogi & Co., Ltd., and is jointly advancing vaccine platform technology development and basic research on development candidates.

UMN Pharma is undergoing a business transformation centered on a strategic partnership with Shionogi & Co., Ltd., aiming for growth through two pillars: in-house development of next-generation biopharmaceuticals and contract manufacturing of biopharmaceuticals. The company entered into a capital and business alliance with Shionogi in October 2017. In Phase 1, which runs through approximately December 2019, the two companies are jointly advancing foundational technology development for infectious disease prevention vaccines and basic research on development candidates. This partnership enables the company to receive milestone fees on a semi-annual basis, establishing a stable revenue foundation.

In priority investment areas, the company is focusing on developing preventive vaccines against emerging infectious diseases such as dengue fever and Zika fever, driven by the expansion of infectious diseases accompanying global warming. The company's differentiation strategy centers on creating "next-generation logical vaccines" that offer higher efficacy and more efficient production than conventional vaccines. The company plans to actively adopt complementary technologies such as adjuvant technology and formulation/drug delivery technology, advancing higher-value product development to increase the likelihood of partnerships with pharmaceutical companies.

In new market development, the company is actively introducing new development candidate targets while reviewing its existing in-house development pipeline (influenza, rotavirus, and norovirus-related vaccines). Notably, based on contract research experience with universities and public research institutions, project candidates have emerged that extend beyond the research stage to anticipate commercialization, which the company leverages as a pathway for introducing new development pipelines. In the contract manufacturing business for biopharmaceuticals, the company operates three facilities—Yokohama Research Institute, Akita Research Institute, and Akita Plant—offering specialized services in CMC development and manufacturing feasibility studies that bridge the research and development stages.

Regarding technological innovation, the company views the transition to Phase 2 of its partnership with Shionogi as a critical objective, advancing foundational technology establishment and selection of specific development candidates. The company plans to establish clinical trial manufacturing and commercial production systems at the Akita Plant, aiming to build an integrated value delivery system from research and development through manufacturing. Additionally, to maximize the value of recombinant protein vaccines, the company is developing efficient production systems that enable antigen dose reduction through the integration of various technologies.